CD4 Therapeutics
Unlocking the Power of Regulatory T-Cells for Autoimmune Disease

A Game-Changer in Autoimmune Therapeutics

CD4 Therapeutics pioneers first-in-class immunotherapy with Tregalizumab, the only monoclonal antibody designed to selectively activate regulatory T-cells (Tregs). With clinical proof-of-concept and high-value indications, we present an exceptionaln investment opportunity in a rapidly expanding market.

Addressing High-Unmet Medical Needs
Millions suffer from immune-driven diseases with no approved treatments or high failure rates of existing biologics. Tregalizumab offers a breakthrough solution where conventional therapies fall short.

>50% failure rates in second-line biologics
Severe safety concerns with steroids & systemic immunosuppressants
No approved therapies for critical indications like immune-driven cancer prevention

Nobel Prize in Physiology or Medicine 2025

They understood how the immune system is kept in check.

The body’s powerful immune system must be regulated, or it may attack our own organs. Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi made groundbreaking discoveries concerning peripheral immune tolerance that prevents the immune system from harming the body. Their discoveries have laid the foundation for a new field of research and spurred the development of new treatments, for example for cancer and autoimmune diseases.

Worldwide exclusive licence

In July 2024, T-Balance Therapeutics GmbH and CD4 Therapeutics GmbH, a Munich-based biotech company, signed an exclusive binding term sheet granting CD4 Therapeutics worldwide rights to develop and commercialize Tregalizumab.

A Multi-Billion-Euro Market Opportunity

Tregalizumab is positioned to lead in high-need markets with clinical validation and a clear commercialization path.

Why This is a €10B+ Opportunity

First-mover advantage in key indications
High medical need with 50% failure rates in biologics
Fast-track regulatory potential in orphan & high-urgency diseases

Key Market Segments:

Oral Lichen Planus (oLP): €5B+
Acute Graft-versus-Host Disease (aGvHD): €3B+
Expansion into RA, AD, IBD (€20B+ total market)

Lean, High-Impact Development Strategy

Focused Initial Indications (oLP & aGvHD) → De-risked, biomarker-driven approach
Expansion into major autoimmune markets (RA, AD, IBD) based on strong data
No direct competitors in Treg activation, creating a defensible market position
Strategic Partnerships & Exit Potential → Pharma licensing, M&A, IPO

Competitive Edge: Why CD4 Stands Apart

First-in-Class Treg Activator – No approved competitors
Strong IP & Regulatory Moat – Orphan designation, biomarker-driven patient selection
Proven Leadership – 80+ years of biotech, drug development, and investment success

Investors & Partners – A High-Impact Opportunity

CD4 Therapeutics offers a de-risked investment in next-generation immunotherapy with clear market leadership potential.

Why Invest in CD4?

First-in-Class Science – The only Treg-activating monoclonal antibody
€10B+ Market Potential – Autoimmune & oncology focus
De-Risked Clinical Strategy – Proven PoC, targeted success
Fast-Track Regulatory Pathways – Orphan drug designation potential
Clear Exit Strategies – Licensing, M&A, IPO

Strategic Investment & Exit Opportunities

Pharma Licensing & Partnerships – High interest from immunology & oncology leaders
Strong Competitive Positioning – No direct competitors in Treg activation
Potential for Co-Development & Strategic Alliances
High-Value Acquisition or IPO Potential

Join the Next Breakthrough in Immunotherapy

Let’s discuss how you can be part of this high-impact investment. Contact us today and meet the Team!

CD4 Therapeutics Unlocking the Power of Regulatory T-Cells for Autoimmune Disease